Biocon confirms US Neulasta rival launch

Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).